A组轮状病毒VP5*和VP8*的表达和免疫学性质研究

轮状病毒是引起婴幼儿腹泻的主要病原,VP4是RV重要的抗原蛋白,在早期病毒与细胞黏附过程中发挥重要作用,包括受体结合和细胞渗透。在细胞黏附过程中,VP4易被切割成VP5*和VP8*两个片段并以此增强病毒感染性。为了深入研究VP5*和VP8*的免疫学性质,进一步评价其应用前景,本研究从TB-Chen株RV基因组中编码VP4蛋白基因上克隆了VP5*和VP8*开放读码框核苷酸序列,构建了表达质粒,在原核大肠杆菌系统中重组表达了VP5*和VP8*蛋白,进一步分析了它们的免疫学性质。结果显示,VP5*和VP8*可在E.coli中高效表达,重组蛋白VP5* (rVP5*)和VP8* (rVP8*)可诱导免疫豚鼠产生特异性血清抗体,这些抗体可特异性识别自身蛋白（rVP5*或rVP8*）,可识别来自的TB-Chen株重组VP4蛋白,并可识别SA11和Wa感染的MA104细胞中合成的病毒VP4蛋白。这些结果表明,rVP5*和rVP8*蛋白具有较高的免疫原性,抗rVP5*和抗rVP8*的抗体具有高度特异性和交叉反应性。     

A组轮状病毒NSP1基因克隆表达及免疫学性质研究

轮状病毒（rotavirus, RV）非结构蛋白1（non structural protein 1, NSP1）在病毒与宿主的相互作用中发挥着重要的功能。运用基因克隆和表达技术在大肠杆菌中表达了TB-Chen株RV NSP1蛋白,进行了NSP1的免疫学性质和RV感染细胞中NSP1蛋白的合成与分布以及NSP1的系统进化和基因分型研究。结果表明,大肠杆菌BL21(DE3)能高效表达重组NSP1蛋白（rNSP1）,rNSP1表达量约占菌体总蛋白的34.4%。rNSP1能诱导免疫豚鼠产生特异性血清抗体。Western blot及免疫荧光检测结果表明,抗rNSP1血清抗体能特异性识别自身蛋白,对SA11、Wa株的NSP1蛋白有交叉反应性;免疫荧光结果还表明,SA11感染的MA104细胞中合成的NSP1蛋白在细胞质中区域化聚集形成辐射状排列的颗粒状结构,而Wa株的NSP1不能形成此样结构。至今发现的A组RV至少可以分为16个不同的NSP1基因型,TB-Chen株NSP1为A2型。不同基因型有独特的敏感宿主范围,同一基因型可能感染不同种动物,同一种动物也可能感染不同基因型。基因型A4型和A16型仅在鸟类病毒株中出现;而且鸟类中只有A4型和A16型。研究结果为进一步研究NSP1蛋白质的结构功能及其应用开发奠定了很好的基础。     

轮状病毒VP4抗原表位在VP6载体蛋白同一位点表达比较研究

目的:评价轮状病毒(RV)VP4两个抗原表位插入VP6载体蛋白同一位点所表达的重组嵌合蛋白免疫学性质及在研制嵌合蛋白疫苗中的意义。方法:采用分子克隆和基因重组技术将RV VP4的两个抗原表位插入到VP6载体蛋白同一位点上,构建重组抗原表达质粒,表达携带不同抗原表位的重组嵌合蛋白,用Western blot和中和试验分析重组嵌合蛋白的抗原反应性和免疫原性。结果:成功构建了两个嵌合蛋白表达质粒,并在大肠杆菌中高效表达;表达的嵌合蛋白可与相应抗体特异性反应;可诱导豚鼠产生特异性血清抗体;抗嵌合蛋白血清抗体可特异性识别载体蛋白VP6F,Wa株病毒的VP6和VP4蛋白,可中和Wa株病毒在MA104细胞上的感染性;结果表明,所构建和表达的两个以VP6为载体的VP4抗原表位嵌合蛋白具有较高抗原反应性和免疫原性;嵌合蛋白携带的VP4抗原表位具有增强载体蛋白免疫原性作用;为研制新型RV重组蛋白疫苗的奠定了较好的基础。     

A组人轮状病毒VP6基因克隆及在大肠杆菌中的高效表达

轮状病毒(rotavirus RV) 结构蛋白VP6位于病毒三层衣壳结构的中间层,在病毒粒子的形成过程中起重要的作用。从临床样品中分离的人轮状病毒TB-Chen株VP6基因通过RT-PCR得到扩增产物。以pET作为表达载体,将VP6蛋白编码基因序列插入到质粒pET中成功构建原核表达质粒pET-VP6。实验表明,带有pET-VP6质粒的大肠杆菌BL21(DE3)可以高效表达目的蛋白VP6,重组表达产物VP6占菌体总蛋白的27.4%, 其分子量约为45 kDa,并且能被豚鼠抗SA11血清抗体识别（Western blot）。这一结果为进一步研究VP6的结构和功能奠定了重要的物质基础。     

A组人轮状病毒NSP2基因的克隆、表达及免疫学性质研究

轮状病毒非结构蛋白NSP2在病毒基因组复制过程中起重要作用。在原核系统中重组表达了来自中国的第一株全基因组被克隆和研究了的轮状病毒NSP2,并进一步对其免疫学性质进行了研究。结果显示,在大肠杆菌中能够高效表达重组NSP2蛋白,而且该蛋白能够诱发豚鼠产生特异性抗体。Western blot和免疫荧光检测表明所得抗体不仅能与该重组NSP2蛋白发生特异性反应,而且可以与轮状病毒SA11株或Wa株感染的MA104细胞中表达的NSP2发生反应。以上这些结果为进一步研究该重组NSP2蛋白的结构、功能及免疫学性质奠定了基础.     

A组轮状病毒多个结构蛋白抗原表位的串联表达及其免疫原性的检测

从北京腹泻婴儿粪便提取的轮状病毒(rotavirus,RV)(T114株)的RNA中,克隆到轮状病毒结构蛋白基因vp4,vp6和vp7的全长cDNA,对它们编码的蛋白质序列和可能的抗原表位肽进行了预测,选择了RV主要抗原蛋白VP7、VP6和VP4的4个抗原表位肽,通过人工合成DNA的方式将这些抗原表位肽基因串联融合成一个阅读框RME(rotavirus multipleepitopes,RME)并构建原核表达载体.大肠杆菌表达的RME在ELISA反应中可被RV多克隆抗体识别,纯化的RME蛋白注射免疫小鼠可诱导特异性免疫应答,产生高滴度的同源氨基酸序列特异抗体和人RV抗体,其中针对RME的IgG抗体滴度达到l∶40 000,针对单个抗原表位EV7、EV6和EV4的IgG抗体滴度达l∶10 000～l∶20 000,针对RV Wa株的IgG抗体滴度较低为l∶2 500,但能特异地中和该病毒对MAC145细胞的侵染.上述结果为新型RV基因工程疫苗的研发提供了论据和基础.     

A组轮状病毒NSP6蛋白表达及免疫学性质研究

轮状病毒(RV）NSP6与NSP5由同一基因片段编码,至今对NSP6 性质了解很少。用基因重组表达和免疫学方法,重组表达了A组人RV NSP6蛋白,进行了NSP6的动物免疫及其抗原反应性、免疫原性研究以及RV感染细胞中NSP6的合成及亚细胞分布研究。研究结果表明,NSP6可在原核系统中高效表达,表达蛋白占菌体总蛋白的34.2%;NSP6免疫豚鼠血清抗体可特异性识别菌体细胞中表达的NSP6和SA11及Wa病毒感染的MA104细胞中合成的NSP6蛋白;病毒感染细胞中合成的NSP6在感染后3h就可检测到,12h表达量达到最高;NSP6在病毒感染细胞质中呈弥散状分布,并主要积聚在细胞核的周围,未观察到毒质体样结构。研究结果对深入了解RV NSP6的结构与功能具有重要的意义,具有重要的潜在应用价值。     

被动免疫轮状病毒NSP4&VP7双抗原重组腺病毒对感染乳鼠的排毒保护作用

为建立小鼠轮状病毒(Rotavirus,RV)感染动物模型,研究可同时表达轮状病毒NSP4 (Nonstructural protein 4)和VP7(Viral protein 7)的重组腺病毒疫苗免疫孕鼠后对新生乳鼠感染RV的被动保护作用.新生乳鼠口服异源株轮状病毒Wa、ZTR-68或SA11株后(分2次给予,每次含5×104 CCID50的RV),观察乳鼠是否有腹泻症状、肠道病理变化,检测乳鼠粪便排毒百分率;另以重组腺病毒rAd-NSP4-VP7免疫孕鼠后,检测母鼠血清抗体产生情况,并对比乳鼠粪便中RV抗原检出率初步评价疫苗的被动免疫保护作用.发现口服异源株RV的乳鼠未出现类似人类婴幼儿感染后的明显腹泻症状,但在粪便中可检测到RV抗原的存在(Wa、ZTR-68攻毒组均超过80％).经rAd-NSP4-VP7被动免疫的乳鼠接受Wa和ZTR-68攻毒后其粪便中的RV检出率比未受到被动免疫保护的对照组降低(P＜0.05).rAd-NSP4-VP7重组腺病毒免疫母鼠可显示出对孕鼠感染RV的被动免疫保护作用.     

传染性法氏囊病病毒VP4蛋白单克隆抗体的制备及鉴定

传染性法氏囊病病毒(IBDV)蛋白VP4在抑制宿主免疫应答中起重要作用,为制备IBDV VP4的单克隆抗体,以实验室保存的融合蛋白His-VP4免疫BALB/c小鼠,经过细胞融合、筛选、亚克隆后获得4株能稳定分泌抗VP4的单抗杂交瘤细胞株,分别命名为3B3、3H11、4C8和4G6,经间接ELISA测定4株单抗的亲和力解离常数分别为4.61×10–11、1.71×10–10、4.26×10–11和5.02×10–11,均为高亲和力抗体。4株单抗的重链类型分别为Ig G1、Ig G1、Ig G2b和Ig G1。进一步以Western blotting鉴定,该4株单抗均能特异地识别IBDV的VP4蛋白,间接免疫荧光和Western blotting试验表明4株单抗均能识别IBDV感染DF-1细胞后产生的VP4蛋白。该单抗为检测IBDV以及研究IBDV VP4的生物学作用奠定了基础。     

草鱼呼肠孤病毒VP7蛋白单克隆抗体的制备与应用

草鱼呼肠孤病毒(Grass carp reovirus, GCRV)是导致该病的主要病原, 研究将Ⅰ型草鱼呼肠孤病毒GCRV-873株的外衣壳蛋白VP7基因进行原核表达, 获得高度纯化VP7重组蛋白, 通过免疫BALB/c小鼠, 首次制备筛选得到高效价单克隆抗体。结果显示, GCRV-I vp7基因可在原核表达系统中高效表达, 主要以包涵体形式存在, 大小约为40 kD。免疫小鼠后筛选到了5株IgG类型阳性杂交瘤细胞株, 其中3株亚型为IgG1, 2株亚型为IgG2a。Western Blot实验和直接免疫荧光实验显示, 该抗体可特异识别GCRV-873, 并且ELISA检测原核重组蛋白的效价高达204800, 亲和常数为4.04×109。研究制备的VP7蛋白单克隆抗体, 为GCRV-I病毒诊断技术开发及病毒感染机制的深入研究提供实验基础。     

研究报告Ⅱ型脊灰病毒抗原表位嵌合蛋白的免疫学研究

目的：评价以轮状病毒（RV）重组VP6蛋白为载体插入Ⅱ型脊髓灰质炎病毒（PV2）VP1蛋白上的1个抗原表位构建而成的嵌合蛋白的体外免疫学性质。 方法：采用分子克隆和基因重组技术将PV2抗原表位插入到RV载体蛋白上,在大肠杆菌中表达并用SDS-PAGE确认表达产物,再通过动物免疫、Western blot、免疫荧光和病毒血清抗体中和试验分析嵌合蛋白的免疫学性质。结果：成功构建了以VP6为载体的PV2抗原表位嵌合蛋白6F/PV₂N₁,并且在E.coli系统中高效表达,嵌合蛋白免疫的豚鼠血清抗体对RV和PV2具备较好的中和活性。结论：以RV VP6为载体构建的嵌合蛋白具有较好的免疫原性,免疫豚鼠产生血清抗体可中和RV和PV2在体外细胞上的感染;进一步为研发RV/PV2嵌合疫苗提供了较好的基础。     

In vitro expression and monoclonal antibody of RNA-dependent RNA polymerase for infectious bursal disease virus

VP1, the RNA-dependent RNA polymerase of infectious bursal disease virus (IBDV), has been suggested to play an essential role in the replication and translation of viral RNAs. In this study, we first expressed the complete VP1 protein gene in Escherichia coli (E. coli), and then the produced polyclonal antibody and four monoclonal antibodies (mAbs) to recombinant VP1 protein (rVP1) were shown to bind the IBDV particles in chicken embryo fibroblast and Vero cells. The epitopic analysis showed that mAbs 1D4 and 3C7 recognized respectively two distinct antigenic epitopes on the rVP1 protein, but two pair of mAbs 1A2/2A12 and 1E1/1H3 potentially recognized another two topologically related epitopes. Immunocytochemical stainings showed that VP1 protein formed irregularly shaped particles in the cytoplasm of the IBDV-infected cells. These results demonstrated that the mAbs to rVP1 protein could bind the epitopes of IBDV particles, indicating that the rVP1 protein expressed in E. coli was suitable for producing the mAb to VP1 protein of IBDV, and that the cytoplasm could be the crucial site for viral genome replication of IBDV.     

Peroral immunization of microencapsulated human VP8 in combination with cholera toxin induces intestinal antibody responses

To develop an orally delivered subunit vaccine for rotavirus infection, a trypsin cleavage product of VP4, recombinant VP8*, was expressed in Escherichia coli. The recombinant VP8* (rVP8*), purified by affinity chromatography, was reactive against human rotavirus positive serum in Western-blot analysis. To further evaluate the immunogenicity of the oral-delivered rVP8*, it was encapsulated with alginate-microsphere and administered in combination with cholera toxin (CT) as a mucosal adjuvant perorally into mice. The ELISPOT assay showed that the number of rVP8*-specific IgG1 antibody secreting cells increased about 3-fold and about 2-fold in spleen and Peyer's patch, respectively as compared to non-immune mice. In addition, the number of rVP8*-specific IgA antibody secreting cells increased about 2-fold in Peyer's patch. Finally, rVP8*-specific IgA antibody response was significantly enhanced in the intestinal fluids from the mice immunized perorally with encapsulated rVP8* and CT. Taken together, these results indicate that rVP8* possessed proper immunogenicity and it would be potentially useful as a subunit vaccine against rotavirus-associated disease through peroral immunization.     

VP37 of white spot syndrome virus interact with shrimp cells

Aims:  To investigate VP37 [WSV 254 of White spot syndrome virus (WSSV) genome] interacting with shrimp cells and protecting shrimp against WSSV infection.
Methods and Results:  VP37 was expressed in Escherichia coli and was confirmed by Western blotting. Virus overlay protein binding assay (VOPBA) technique was used to analyse the rVP37 interaction with shrimp and the results showed that rVP37 interacted with shrimp cell membrane. Binding assay of recombinant VP37 with shrimp cell membrane by ELISA confirmed that purified rVP37 had a high-binding activity with shrimp cell membrane. Binding of rVP37 to shrimp cell membrane was a dose-dependent. Competition ELISA result showed that the envelope protein VP37 could compete with WSSV to bind to shrimp cells. In vivo inhibition experiment showed that rVP37 provided 40% protection. Inhibition of virus infection by rVP37 in primary cell culture revealed that rVP37 counterparted virus infection within the experiment period.
Conclusions:  VP37 has been successfully expressed in E . coli . VP37 interacted with shrimp cells.
Significance and Impact of the Study:  The results suggest that rVP37 has a potential application in prevention of virus infection.     

Prokaryotic expression of chicken infectious anemia apoptin protein and characterization of its polyclonal antibodies

In the present study recombinant VP3 (rVP3) was expressed in E. coli BL21 (DE3) (pLysS) and its polyclonal antibodies were characterized. SDS-PAGE analysis revealed that the expression of recombinant protein was maximum when induced with 1.5 mM IPTG for 6 h at 37 degrees C. The 6xHis-tagged fusion protein was purified on Ni-NTA and confirmed by Western blot using CAV specific antiserum. Rabbits were immunized with purified rVP3 to raise anti-VP3 polyclonal antibodies. Polyclonal serum was tested for specificity and used for confirming expression of VP3 in HeLa cells transfected with pcDNA.cav.vp3 by indirect fluorescent antibody test (IFAT), flow cytometry and Western blot. Available purified rVP3 and polyclonal antibodies against VP3 may be useful to understand its functions which may lead to application of VP3 in cancer therapeutics.     

重组SCIRR39多克隆抗体的制备及检测

目的：在大肠杆菌中表达大鼠脊髓损伤与修复蛋白39（SCIRR39）的C端抗原表位,并制备其多克隆抗体。方法：从大鼠脊髓全横断损伤脊髓cDNA中扩增1386bp的Scirr39基因编码框,亚克隆该基因编码蛋白C端359～461位氨基酸残基的DNA片段,插入表达载体,转化大肠杆菌BL21（DE3）,IPTG诱导表达,SDS-PAGE分析表达情况,切胶纯化目的蛋白;利用多克隆抗体制备技术,制备重组SCIRR39蛋白的多克隆抗体;用ELISA方法检测抗体效价,Western印迹检测抗体的特异性。结果：SCIRR39蛋白C端抗原表位与GST的融合蛋白在大肠杆菌中以可溶形式高表达,相对分子质量为37．9×103;获得抗SCIRR39蛋白C端抗原表位的兔抗血清,其效价达到1：104;Western印迹显示多克隆抗体能特异识别重组SCIRR39蛋白的C端抗原表位。结论：在原核系统中表达纯化了重组SCIRR39抗原表位蛋白,制备的重组蛋白多克隆抗体将用于检测SCIRR39在脊髓损伤过程中的表达变化。     

肠道病毒71型外壳蛋白VP1全长在大肠杆菌中的高效表达及初步活性测定

目的:重组表达肠道病毒71型(EV71)外壳蛋白VP1全长,用于研制血清学检测试剂和疫苗研发。方法:在获得EV71全长基因并测序正确的基础上,将外壳蛋白VP1全长基因克隆到表达载体pET28a(+)上,构建重组表达质粒pET28a(+)/VP1,转化大肠杆菌BL21,IPTG诱导表达,利用Ni2+亲和层析柱对重组蛋白进行纯化,采用双抗原夹心检测技术评价重组抗原与27份EV71抗体阳性血清和18份阴性血清的反应情况。结果:重组EV71-VP1蛋白在大肠杆菌中诱导6 h后可获得高效表达,能与27份EV71抗体阳性血清中的21份发生阳性反应,EV71双抗原夹心检测与中和血清测试结果具有很好的一致性(P0.05)。结论:实现了肠道病毒71型外壳蛋白VP1的高效表达,为肠道病毒71型诊断试剂和疫苗的研究奠定了基础。     

Characterization and Diagnostic Use of a Monoclonal Antibody for VP28 Envelope Protein of White Spot Syndrome Virus

The gene encoding the VP28 envelope protein of White spot syndrome virus (WSSV)was cloned into expression vector pET-30a and transformed into the Escherichia coli strain BL21.After induction,the recombinant VP28 (rVP28) protein was purified and then used to immunize Balb/c mice for monoclonal antibody (MAb) production.It was observed by immuno-electron microscopy the MAbs specific to rVP28 could recognize native VP28 target epitopes of WSSV and dot-blot analysis was used to detect natural WSSV infection.Competitive PCR showed that the viral level was approximately 104 copies/mg tissue in the dilution of gill homogenate of WSSV-infected crayfish at the detection limit of dot-blot assay.Our results suggest that dot-blot analysis with anti-rVP28 MAb could rapidly and sensitively detect WSSV at the early stages of WSSV infection.     

人免疫缺陷病毒早期蛋白Nef的表达、纯化及免疫原性研究

目的：通过原核细胞表达人免疫缺陷病毒（HIV）Nef抗原,制备特异抗血清,为Nef抗原检测提供技术方法。方法：以HIVBotswana毒株基因组为模板,用PCR法获得Nef蛋白编码基因,将其克隆到pET30a载体中,在大肠杆菌中表达Nef融合蛋白;用纯化的融合蛋白免疫BALB／c小鼠获得抗血清,用真核表达的Nef抗原对其特异性进行分析。结果：构建的Nef融合基因在大肠杆菌中获得表达,相对分子质量约为36x103,免疫BALB／c小鼠获得针对融合蛋白的高效价抗血清,ELISA抗体滴度为1：6400;免疫荧光和Westemblot检测表明,该抗血清能特异地与重组痘苗病毒表达的Nef抗原反应。结论：在大肠杆菌中表达了HIVNef融合蛋白,制备了Nef融合蛋白的高效价小鼠免疫血清,该血清能特异性识别HIVNef抗原,为HlVNef抗原检测提供了技术方法。     

Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection

Acute human parvovirus B19 infection is followed by an antibody response to the structural proteins of the viral capsid (VP1 and VP2). We used 80 sera collected from 58 erythema infectiosum and 6 transient aplastic crisis patients to test IgM and IgG antibodies against these two proteins in an immunofluorescence assay (IFA) using Sf9 cells infected with recombinant baculovirus expressing either VP1 or VP2 antigen. Although less sensitive than IgM capture enzyme immunoassay using native antigen (MACEIA), we could detect anti-VP1 or anti-VP2 IgM antibodies by IFA in 49 patients with acute infection (76.6%). Detection of IgG anti-VP1 and anti-VP2 by IFA, however, was as sensitive as IgG detection by indirect enzyme immunoassay. By applying IgG avidity IFA to sera of the 15 IgM IFA negative patients we were able to confirm acute infection in further 12 cases by IFA. Overall, acute infection was confirmed by IFA in 61 (95.3%) of the 64 patients.